The Impact of Supplemental Antioxidants on Visual Function in Nonadvanced Age-Related Macular Degeneration: A Head-to-Head Randomized Clinical Trial

被引:40
|
作者
Akuffo, Kwadwo Owusu [1 ]
Beatty, Stephen [1 ]
Peto, Tunde [2 ]
Stack, Jim [1 ]
Stringham, Jim [3 ]
Kelly, David [1 ]
Leung, Irene [4 ,5 ]
Corcoran, Laura [1 ]
Nolan, John M. [1 ]
机构
[1] Waterford Inst Technol, Nutr Res Ctr Ireland, Sch Hlth Sci, Macular Pigment Res Grp, Waterford, Ireland
[2] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland
[3] Univ Georgia, Dept Physiol & Pharmacol, Nutr Neurosci Lab, Athens, GA 30602 USA
[4] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[5] UCL Inst Ophthalmol, London, England
基金
欧洲研究理事会;
关键词
randomized clinical trial; lutein; zeaxanthin; meso-zeaxanthin; macular pigment; age-related macular degeneration; visual function; visual acuity; contrast sensitivity; NEI VFQ-25; photostress recovery time; reading performance; glare disability; retinal straylight; BASE-LINE-CHARACTERISTICS; CONTRAST SENSITIVITY; EYE DISEASE; SURGICAL REMOVAL; ZEAXANTHIN; PIGMENT; LUTEIN; CAROTENOIDS; CATARACT; PREVALENCE;
D O I
10.1167/iovs.16-21192
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. The purpose of this study was to evaluate the impact of supplemental macular carotenoids (including versus not including meso-zeaxanthin) in combination with coantioxidants on visual function in patients with nonadvanced age-related macular degeneration. METHODS. In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso-zeaxanthin; n = 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61). Visual function was assessed using best-corrected visual acuity, contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading performance, and the National Eye Institute Visual Function Questionnaire-25. Macular pigment was measured using customized heterochromatic flicker photometry. RESULTS. There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881). Statistically significant improvements in several secondary outcome visual function measures (letter CS at 1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at 1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time; retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05, for all), and were statistically comparable between interventions (P > 0.05, for all). Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05). CONCLUSIONS. Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function.
引用
收藏
页码:5347 / 5360
页数:14
相关论文
共 50 条
  • [1] Improving Function in Age-related Macular Degeneration A Randomized Clinical Trial
    Rovner, Barry W.
    Casten, Robin J.
    Hegel, Mark T.
    Massof, Robert W.
    Leiby, Benjamin E.
    Ho, Allen C.
    Tasman, William S.
    OPHTHALMOLOGY, 2013, 120 (08) : 1649 - 1655
  • [2] Bevacizumab vs ranibizumab treatment for age-related macular degeneration - A head-to-head comparison is needed
    Jampol, Lee M.
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (04) : 557 - 558
  • [3] Improving function in Age-Related Macular Degeneration: Design and methods of a randomized clinical trial
    Rovner, Barry W.
    Casten, Robin J.
    Hegel, Mark T.
    Massof, Robert W.
    Leiby, Benjamin E.
    Tasman, William S.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (02) : 196 - 203
  • [4] Randomized trial of radiation for age-related macular degeneration
    Char, DH
    Irvine, AI
    Posner, MD
    Quivey, J
    Phillips, TL
    Kroll, S
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 127 (05) : 574 - 578
  • [5] Influence/impact of lutein complex (marigold flower and wolfberry) on visual function with early age-related macular degeneration subjects: A randomized clinical trial
    Peng, Mei-Ling
    Chiu, Hui-Fang
    Chou, Hsuan
    Liao, Hui-Ju
    Chen, Shyan-Tarng
    Wong, Yue-Ching
    Shen, You-Cheng
    Venkatakrishnan, Kamesh
    Wang, Chin-Kun
    JOURNAL OF FUNCTIONAL FOODS, 2016, 24 : 122 - 130
  • [6] Impact of Treating Age-Related Macular Degeneration before Visual Function Is Impaired
    Aichi, Risa
    Nagai, Norihiro
    Ohkoshi, Kishiko
    Ozawa, Yoko
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [7] Antioxidants and minerals for age-related macular degeneration
    Ebell, Mark H.
    AMERICAN FAMILY PHYSICIAN, 2006, 74 (05) : 750 - 750
  • [8] Repeatability of visual function measures in age-related macular degeneration
    Aslam, Tariq
    Mahmood, Sajjad
    Balaskas, Konstantinos
    Patton, Niall
    Tanawade, Rajeev G.
    Tan, Shi Zhuan
    Roberts, Stephen A.
    Parkes, Jeremy
    Bishop, Paul N.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (02) : 201 - 206
  • [9] Repeatability of visual function measures in age-related macular degeneration
    Tariq Aslam
    Sajjad Mahmood
    Konstantinos Balaskas
    Niall Patton
    Rajeev G. Tanawade
    Shi Zhuan Tan
    Stephen A. Roberts
    Jeremy Parkes
    Paul N. Bishop
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 201 - 206
  • [10] Low Vision Depression Prevention Trial in Age-Related Macular Degeneration A Randomized Clinical Trial
    Rovner, Barry W.
    Casten, Robin J.
    Hegel, Mark T.
    Massof, Robert W.
    Leiby, Benjamin E.
    Ho, Allen C.
    Tasman, William S.
    OPHTHALMOLOGY, 2014, 121 (11) : 2204 - 2211